Select your timezone:

Transmission of Diseases

Thursday October 19, 2023 - 11:00 to 12:00

Room: South Seas Ballroom A/B

P6.3 From design to clinical trial: An application to estimate the residual risk of unexpected infections from increased viral risk donors

Kathrin A Lawson, Australia

Donation Specialist Coordinator
Donate Life Victoria

Abstract

From design to clinical trial: An application to estimate the residual risk of unexpected infections from increased viral risk donors

Martin Dutch1,2, Greg Wadley3, Jon C Knott1,2.

1 Emergency Department., Royal Melbourne Hospital, Melbourne, Australia; 2Department of Critical Care, University of Melbourne, Melbourne, Australia; 3School of Computing and Information Systems, University of Melbourne, Melbourne, Australia

Introduction: Despite the rarity of unexpected donor-derived infections from increased viral risk organ donors (IVRD), and the benefits of timely transplantation, there is ongoing reluctance by some patients and clinicians to accept IVRD offers. Estimation of residual risk is a complex multi-stage process, that is modulated by donor factors such as length of critical care stay.

Objectives: In this presentation, we describe and demonstrate the design priorities and development of a web-based and iOS-based application to calculate residual risk.

Method: We adopted a participatory design methodology to develop the application. Participants included donation and transplantation clinicians, coordinators, administrators, and specialist consultants. Methods included surveys, workshops, interviews, and usability studies.

Results: Based on insight from the design process, we developed both a web-based and iOS application that calculates, visualises, contextualises, and facilitates the sharing of residual risk estimates. The application incorporates a database of peer-reviewed studies, risk infographic visualisations, organ transplant-specific risk comparators, a variety of sharing options including exports compatible with upload to the Electronic Donor Record, and a bespoke recipient risk handout. DonateLife Victoria is currently sponsoring a trial of the application for use in Victoria.

Conclusion: Donation and Transplantation professionals have identified a series of design features that have been integrated into the application to estimate the residual risk of unexpected disease transmission from increased viral risk donors. A clinical trial of the application is currently underway in Victoria, and is expected to conclude mid 2023.

Sponsors


© 2025 ISODP 2023